高尿酸血症
黄嘌呤氧化酶
尿酸
肠道菌群
体内
药理学
罗伊乳杆菌
核苷
生物化学
生物
微生物群
痛风
益生菌
化学
代谢组
黄嘌呤
体外
基因组
别嘌呤醇
肾
脂多糖
次黄嘌呤
肠道通透性
黄嘌呤氧化酶抑制剂
毒物
作者
Xin Hua Zhou,Ming Zhang,Jun Zhou,Jiaojiao Han
摘要
BACKGROUND Hyperuricemia, a major risk factor for gout and kidney disease, requires safe and effective dietary strategies beyond conventional pharmacotherapy. This study investigated the multi‐target effects of the food‐grade probiotic Limosilactobacillus reuteri RE225 on hyperuricemia. It was evaluated in vitro for xanthine oxidase (XOD) inhibition and nucleoside degradation, and in vivo in hyperuricemic mice gavaged daily with low or high doses of RE225 (1 × 10 6 or 1 × 10 9 CFU). Serum uric acid (UA), XOD activity, inflammatory cytokines, intestinal permeability markers – fluorescein isothiocyanate–dextran (FITC‐dextran), lipopolysaccharide (LPS), and d ‐lactate – and renal TLR4/NF‐ κ B signaling were quantified. Fecal metagenomics and Kyoto Encyclopedia of Genes and Genomes ortholog (KO) profiling were used to assess microbiota structure and function. RESULTS Limosilactobacillus reuteri RE225 dose‐dependently inhibited XOD and degraded more than 50% of nucleosides in vitro . In vivo , RE225 reduced serum urate, restored intestinal barrier function, suppressed inflammation, and downregulated renal TLR4/NF‐ κ B signaling. Metagenomic analysis showed that L. reuteri RE225 reversed UA‐induced loss of microbial richness and evenness, enriched Faecalibaculum and Erysipelotrichaceae , and shifted functional profiles from proliferation‐ and inflammation‐related modules (K02315, K02970, and K03496) toward carbohydrate utilization and genetic stability pathways (K01784 and K07491). CONCLUSION Limosilactobacillus reuteri RE225 shows promise as a dietary intervention for the management of hyperuricemia. © 2026 Society of Chemical Industry.
科研通智能强力驱动
Strongly Powered by AbleSci AI